# Low-molecular-weight heparin-induced thrombocytopenia with multisite embolism: successful management with argatroban and dabigatran – a case report and literature review

**Authors:** Huixin Zhao, Xiaowan Tang, Xitao Song

PMC · DOI: 10.3389/fphar.2025.1573840 · Frontiers in Pharmacology · 2025-07-11

## TL;DR

A rare case of low-molecular-weight heparin-induced thrombocytopenia with embolism was successfully managed using argatroban and dabigatran.

## Contribution

This case report highlights the successful treatment of LMWH-induced HIT with argatroban followed by dabigatran.

## Key findings

- Discontinuation of heparin and initiation of argatroban therapy improved the patient's condition.
- Transition to dabigatran prevented further embolic complications and mortality.
- Platelet transfusion should be used cautiously in HIT to avoid worsening thrombosis.

## Abstract

Heparin-induced thrombocytopenia (HIT) is a rare but potentially life-threatening complication, with an incidence ranging from approximately 0.2%–5.0%. The risk of HIT associated with low-molecular-weight heparin (LMWH) is nearly ten times lower than that of unfractionated heparin (UFH). However, LMWH can still induce severe thrombocytopenia and thromboembolic events. This study presents a rare case of LMWH-induced severe type II thrombocytopenia complicated by multiple thromboembolic events. An elderly patient developed HIT following LMWH administration and experienced worsening embolic symptoms after platelet transfusion. The patient received timely discontinuation of heparin analogues and initiation of argatroban therapy with close monitoring of activated partial thromboplastin time (APTT). This was followed by a transition to dabigatran etexilate, which successfully prevented life-threatening embolic complications, limb amputation, and mortality. This case underscores the importance of maintaining a high level of clinical vigilance despite the rarity of LMWH-induced HIT. Once HIT is diagnosed, all forms of heparin should be discontinued immediately, and the decision to administer platelet transfusion should be made with caution to prevent exacerbation of thrombosis. This study provides valuable insights into the early recognition and optimal management of LMWH-induced HIT.

## Linked entities

- **Chemicals:** argatroban (PubChem CID 92722), dabigatran etexilate (PubChem CID 135565674)
- **Diseases:** thrombocytopenia (MONDO:0002049)

## Full-text entities

- **Diseases:** thrombocytopenia (MESH:D013921), embolic complications (MESH:D004617), thromboembolic (MESH:D013923), HIT (MESH:C562865), thrombosis (MESH:D013927)
- **Chemicals:** Heparin (MESH:D006493), argatroban (MESH:C031942), LMWH (MESH:D006495), dabigatran (MESH:D000069604)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12289472/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12289472/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12289472/full.md

---
Source: https://tomesphere.com/paper/PMC12289472